CDAK
Price:
$0.057
Market Cap:
$2.83M
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington...[Read more]
Industry
Biotechnology
IPO Date
2020-10-14
Stock Exchange
NASDAQ
Ticker
CDAK
According to Codiak BioSciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -122.32%. This represents a change of 592.07% compared to the average of -17.67% of the last 4 quarters.
The mean historical ROE of Codiak BioSciences, Inc. over the last ten years is -274.44%. The current -122.32% ROE has changed -55.43% with respect to the historical average. Over the past ten years (40 quarters), CDAK's ROE was at its highest in in the June 2020 quarter at 119.99%. The ROE was at its lowest in in the December 2020 quarter at -123.27%.
Average
-274.44%
Median
-219.43%
Minimum
-610.50%
Maximum
-48.40%
Discovering the peaks and valleys of Codiak BioSciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 645.98%
Maximum Annual ROE = -48.40%
Minimum Annual Increase = -87.25%
Minimum Annual ROE = -610.50%
Year | ROE | Change |
---|---|---|
2021 | -77.81% | -87.25% |
2020 | -610.50% | 69.09% |
2019 | -361.04% | 645.98% |
The current ROE of Codiak BioSciences, Inc. (CDAK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-349.78%
5-year avg
-274.44%
10-year avg
-274.44%
Codiak BioSciences, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Codiak BioSciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Codiak BioSciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Codiak BioSciences, Inc.'s ROE?
How is the ROE calculated for Codiak BioSciences, Inc. (CDAK)?
What is the highest ROE for Codiak BioSciences, Inc. (CDAK)?
What is the 3-year average ROE for Codiak BioSciences, Inc. (CDAK)?
What is the 5-year average ROE for Codiak BioSciences, Inc. (CDAK)?
How does the current ROE for Codiak BioSciences, Inc. (CDAK) compare to its historical average?